These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19968656)

  • 1. Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis.
    Imkampe AK; Bates T
    Breast J; 2010; 16(2):156-61. PubMed ID: 19968656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of body mass index in locally advanced breast cancer.
    Dawood S; Broglio K; Gonzalez-Angulo AM; Kau SW; Islam R; Hortobagyi GN; Cristofanilli M
    Clin Cancer Res; 2008 Mar; 14(6):1718-25. PubMed ID: 18347172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.
    Bahl M; Ennis M; Tannock IF; Hux JE; Pritchard KI; Koo J; Goodwin PJ
    Breast Cancer Res Treat; 2005 Nov; 94(2):135-44. PubMed ID: 16261412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S; Gutierrez J; Avisar E
    Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
    Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
    Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of reexcision for positive margins in optimizing local disease control after breast-conserving surgery for cancer.
    Aziz D; Rawlinson E; Narod SA; Sun P; Lickley HL; McCready DR; Holloway CM
    Breast J; 2006; 12(4):331-7. PubMed ID: 16848842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index in relation to ovarian cancer survival.
    Zhang M; Xie X; Lee AH; Binns CW; Holman CD
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1307-10. PubMed ID: 15894691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors.
    Skírnisdóttir I; Sorbe B
    Acta Obstet Gynecol Scand; 2010; 89(1):101-7. PubMed ID: 19878086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series.
    Truong PT; Lesperance M; Li KH; MacFarlane R; Speers CH; Chia S
    Ann Surg Oncol; 2010 Aug; 17(8):2138-46. PubMed ID: 20151215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer in the elderly: treatment of 1500 patients.
    Livi L; Paiar F; Saieva C; Simontacchi G; Nori J; Sanchez L; Santini R; Mangoni M; Fondelli S; Distante V; Bianchi S; Biti G
    Breast J; 2006; 12(4):353-9. PubMed ID: 16848846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
    Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
    Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
    Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
    Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.